CHAARTED
ADT + Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
Patient / Population Intervention / Exposure Comparison Outcome
In 790 patients with metastatic hormone-sensitive prostate cancer, ADT + docetaxel improved overall survival compared with ADT alone.
N
790
Design
Open-label RCT
Endpoint
Overall survival
Relevance
2
ResultOS 57.6 vs 44.0 months (HR 0.61). High-volume subgroup: 51.2 vs 34.4 months (HR 0.63). No clear benefit in low-volume at long-term follow-up.
Sweeney CJ, et al. N Engl J Med. 2015;373(8):737-746; Kyriakopoulos CE, et al. J Clin Oncol. 2018;36(11):1080-1087. 10.1056/NEJMoa1503747
Discussion & critique
Opened the era of intensification on top of ADT in mHSPC. STAMPEDE/LATITUDE and triplet regimens (ARASENS, PEACE-1) have built on this scaffold.